FOTIVDA (tivozanib)
Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC)
ApprovedActive
Key Facts
Indication
Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC)
Phase
Approved
Status
Active
Company
About AVEO Oncology
AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.
View full company profile